Pharmaceuticals

Elanco Animal Health

Elanco EVP Rajeev A. Modi Buys Nearly 5,000 Shares, Total Holdings Rise to Approx 160k

Elanco CEO Jeffrey N. Simmons Buys 4,971 Shares and Receives 142 DSUs

Elanco Launches New Anti-IL-31 Monoclonal Antibody Befrena for Canine Allergic Dermatitis

Elanco Animal Health released FY2026 Q1 earnings on May 6 During-Market EST, actual revenue USD 1.371 B (forecast USD 1.276 B), actual EPS USD 0.11 (forecast USD 0.096)

Elanco Animal Health Reports Strong Q1 2026 Earnings

Elanco Reports Continued Strong Growth in 2025 Annual Report

Elanco Animal Health to Release FY2026 Q1 Earnings on May 6 During-Market EST, Forecast Revenue USD 1.276 B, EPS USD 0.096

Elanco Animal Health released FY2025 earnings on February 24 During-Market (EST), actual revenue USD 4.715 B (forecast USD 4.67 B), actual EPS USD -0.47 (forecast USD -0.0783)

Elanco Animal Health released FY2025 Q4 earnings on February 24 During-Market EST, actual revenue USD 1.144 B (forecast USD 1.094 B), actual EPS USD -0.56 (forecast USD -0.154)

Elanco releases 2025 10-K report

Elanco Animal Health to Release FY2025 Q4 Earnings on February 24 During-Market (EST), Forecast Revenue USD 1.094 B, EPS USD -0.154

Piper Sandler upgrades Elanco stock rating and price target

Wall Street Zen Upgrades Elanco to Strong Buy

Stifel Nicolaus gives Elanco Animal Health a Buy Rating

New York State Teachers Retirement System Invests $5.5 Million in Elanco Animal Health in Q3

Elanco's New Pet Medication Befrena™ Approved by USDA

Elanco Receives FDA Conditional Approval for Credelio Quattro-CA1

Jim Cramer and Barclays Analyst Recommend Elanco Animal Health Stock

Elanco to Invest $400 Million in US Business Over Next Five Years

Elanco VP Modi Rajeev A Buys 4,500 Shares

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

ELAN

Elanco Animal Health has launched Befrena™ (tirnovetmab), a new anti-IL-31 monoclonal antibody for treating canine allergic dermatitis. The product, which offers 6 to 8 weeks of itch relief and starts working within 24 hours, is currently being used by select veterinarians. This launch expands Elanco's dermatology portfolio in the $1.3 billion U.S. canine dermatology market, following the approval from the USDA. Early results from veterinarians indicate positive outcomes for dogs suffering from allergies.

StockTitan

Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market | ELAN Stock News

IBBQ

ARKG

Morgan Stanley's Erin Wright has reaffirmed a Hold rating on Elanco Animal Health (ELAN) with a price target of $23.00. The analyst consensus suggests a Strong Buy rating for Elanco, with an average price target of $29.18. Wright has a 14.7% average return and a 62.50% success rate on stock recommendations.

Tip Ranks

Health Care Select Sector SPDR

Invesco Nasdaq Biotechnology ETF

iShares Global Healthcare

VG Health

iShares Biotechnology ETF

iShares US Pharma

Ark Genomic Revolution ETF

Morgan Stanley

Henry Schein

Molina Healthcare

Cencora

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Morgan Stanley Reaffirms Their Hold Rating on Elanco Animal Health (ELAN)

PAHC

ECO Animal Health Group (LON:EAH) shares fell below their 200-day moving average of GBX 98.93, trading as low as GBX 92 before closing at GBX 93.78. The company has a market cap of £62.83 million and a price-to-earnings ratio of 21.33. Analysts maintain a "buy" rating with an average price target of GBX 160. Despite the current dip, the company is recognized for its veterinary pharmaceuticals and has a strong R&D pipeline.

Market Beat

Phibro Animal Health

ECO Animal Health Group (LON:EAH) Share Price Crosses Below 200 Day Moving Average   - Here's Why

JPMorgan Chase & Co. has raised its price target for Elanco Animal Health (NYSE:ELAN) from $28.00 to $30.00, maintaining an "overweight" rating. This new target suggests a potential upside of 25.03% from the previous close. Other analysts have also issued positive ratings, with an average rating of "Moderate Buy" and a price target of $28.10. Elanco's stock recently traded down to $24.00, despite a strong quarterly earnings report showing $0.40 EPS, beating estimates. Institutional investors hold 97.48% of the company's stock.

JPMorgan Chase

Citigroup

KeyCorp

UBS Group AG

Piper Sandler Cos

Zoetis

T. Rowe Price

Invesco

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

Elanco Animal Health (NYSE:ELAN) Given New $30.00 Price Target at JPMorgan Chase & Co.

Elanco Animal Health shares rose 9.33% to $25.13 following strong Q1 earnings and emergency use approvals for its products, Negasunt Powder and Tanidil. The company reported adjusted earnings of 40 cents, surpassing expectations, and sales of $1.37 billion, also above consensus. Elanco raised its full-year earnings guidance to $1.03-$1.09 per share and sales guidance to $5.01 billion-$5.085 billion, reflecting a solid start to the year and positive trends in both pet and farm animal segments.

benzinga_article

Novavax

Primoris

Elanco Animal Health Moves Higher On Earnings Strength And Product Momentum

William Blair analyst Brandon Vazquez has reiterated a Buy rating on Elanco (ELAN) following a strong Q1 performance that exceeded sales and EBITDA forecasts. He cites robust growth in the farm animal segment and an optimistic outlook for U.S. pet health growth as key factors. Management has raised full-year guidance, and Vazquez finds the current valuation attractive at about 20 times his 2027 EPS estimate. Bank of America Securities also maintains a Buy rating with a $30 price target.

- Analyst Brandon Vazquez from William Blair maintains a bullish outlook on Elanco stock, issuing a buy rating due to strong first-quarter performance surpassing sales and EBITDA forecasts.  
- Vazquez notes that the company's organic growth in the farm animal segment and expectations for an acceleration in pet health growth in the U.S. are key catalysts for future stock price increases.  
- Additionally, Bank of America Securities also issued a buy rating on April 28, setting a target price of $30.00 for the stock.

Analyst Reiterates Buy on Elanco After Strong Q1 Beat, Raised Guidance, and Attractive Valuation

VEGI

FTAG

Elanco Animal Health shares are trading higher after reporting better-than-expected Q1 financial results and raised its FY26 guidance above estimates.

iShares MSCI Agriculture Producers ETF

First Trust Indxx Global Agri

VanEck Agribusiness ETF

Elanco Animal Health(ELAN.US)